Results 161 to 170 of about 5,531,000 (262)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

The outcomes of electronic personal health records in patients with heart failure or coronary artery disease

ESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka, Satoshi Yasuda, Takashi Shiroto, Saori Yamamoto, Haruka Sato, Yuhi Hasebe, Shigeo Godo, Makoto Nakano, Tomohiko Shindo, Kensuke Nishimiya, Kiyotaka Hao, Jun Takahashi, Keisuke Ido, Yoichi Kakuta, Hiroaki Shimizu, Hiroaki Shimokawa, Masaharu Nakayama   +16 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Trends and Racial-Geographic Disparities in Coexisting Coronary Artery Disease (CAD) and Heart Failure (HF) Related Mortality Among U.S. Adults, 1999-2024. [PDF]

Health Sci Rep
Bhagia S, Mustafa MS, Khalid D, Baig ZM, Ahmed N, Khuhro MM, Khan HN, Mubashir D, Arsalan S, Khan MB, Aminpoor H.   +10 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India. [PDF]

Sci Rep
Bharath G, Preethi L, Suriyam Nagappan A, Kalpana SR, Christopher R, Munirajan AK.   +5 more
europepmc   +1 more source

Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) - What Benchmark are We Aiming at in Continuing Medical Education (CME)? [PDF]

J Eur CME, 2020
Hagen B, Griebenow R.
europepmc   +1 more source

Carotid ultrasound assessment of patients with coronary artery disease: a useful index for risk

, 2005
Roman Komorovsky, Alessandro DesideriCardiovascular Research Foundation, S Giacomo Hospital, Castelfranco Veneto, ItalyAbstract: Carotid disease is a common finding in patients with coronary artery disease (CAD) and its presence is associated with worse ...
Roman Komorovsky, Alessandro Desideri
core  

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Coronary Microvascular Dysfunction and Risk of Cardiovascular Events in Type 2 Diabetes Without Obstructive Coronary Artery Disease (CAD): A Prospective Study. [PDF]

Cureus
Abrar U, Khan MN, Farooq S, Wakil H, Azhar Ghauri H, Khanam Sherwani MQ, Akbar I, Ali H, Akhtar R, Raza A.   +9 more
europepmc   +1 more source